Faecal microbiota transplantation: A sui generis biological drug, not a tissue

Annales Pharmaceutiques Francaises

Volumn 72, Issue 4, 2014, Pages 217-220

  Megerlin, F ^a,b,f,g   Fouassier, E ^f,g   Lopert, R ^c,d   Bourlioux, P ^e,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b School of Public Health   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d LWC Health Pty Ltd   (Australia)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Université Paris Sud   (France)

^g Academie nationale de pharmacie   (France)

Author keywords

Drug; Faecal microbiota transfer; Law; Microbiome; Policy; Tissue

Indexed keywords

NEW DRUG; BIOLOGICAL PRODUCT;

ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM CULTURE; BIODIVERSITY; BIOLOGICAL ACTIVITY; BIOREACTOR; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONSULTATION; DRUG MANUFACTURE; ECONOMIC ASPECT; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES MICROFLORA; HUMAN; INFECTION CONTROL; INFECTION RISK; INTESTINE FLORA; MICROBIOLOGY; MICROBIOME; NASOGASTRIC TUBE; NONHUMAN; PHARMACIST; SYMBIOSIS; TRANSPLANTATION; TREATMENT INDICATION; BACTERIUM IDENTIFICATION; FUNGUS; HUMAN CELL CULTURE; MEDICAL SOCIETY; METABOLITE; MUCUS; PRACTICE GUIDELINE; TISSUE TRANSPLANTATION; VIRUS; ANIMAL; CLOSTRIDIUM INFECTIONS; LEGISLATION AND JURISPRUDENCE;

ANIMALS; CLOSTRIDIUM INFECTIONS; FECES; HUMANS; TISSUE TRANSPLANTATION;

EID: 84903783846     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2014.04.008     Document Type: Article

References (22)

1. Van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent C. difficile. N Engl J Med 2013, 368:407-415.
2. Barbut F., Collignon A., Butel M.J., Bourlioux P. Le transfert de flore digestive: une revue de la littérature. Ann Pharm Fr 2014, [in press].
3. Smith M.B., Coleen K., Alm E.J. Policy: how to regulate faecal transplants. Nature 2014, 506:290-291. 10.1038/506290a.
4. FDA. Guidance for industry - Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat C. difficile infection not responsive to standard therapies (February 2014 Guidance for consultation). Center for Biologics Evaluation and Research, FDA doc. 79 FR 10814.
5. NICE. Interventional procedure overview of faecal microbiota transplant for recurrent Clostridium difficile infection IP 1096 [IPG 485] (2013).
6. ANSM (Comité scientifique temporaire sur la transplantation de microbiote fécal) La transplantation de microbiote fécal et son encadrement dans les essais cliniques 2014.
7. Zhang F., Luo W., Shi Y., Fan Z., Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012, 107:1755. [author reply p. 1755-6].
8. Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C., Knight R., Gordon J.I. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 2007, 449(7164):804-810.
9. For the European Union, (accessed March 2014). http://cordis.europa.eu/news/rcn/30004%20fr.html.
10. Wilson D.S., Sober E. Reviving the superorganism. J Theor Biol 1989, 136(3):337-356.
11. Blaser M., Bork P., Fraser C., Knight R., Wang J. The microbiome explored: recent insights and future challenges. Nat Rev Microbiol 2013, 11:213-217.
12. Evans J.M., Morris L.S., Marchesi J.R. The gut microbiome: the role of a virtual organ in the endocrinology of the host. J Endocrinol 2013, 218:R37-R47.
13. Heintz C., Mair W. You are what you host: microbiome modulation of the aging process. Cell 2014, (156):408-411.
14. Kuhn T.S. The structure of scientific revolutions (1962) 1972, Flammarion, Paris.
15. Bourlioux P., Megerlin F., Corthier G., Gobert J.-G., Butel M.-J. Pourquoi la flore intestinale a-t-elle vocation à devenir un médicament ?. Ann Pharm Fr 2014, [in press].
16. Trevor D., Lawley, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing C. difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
17. Petrof E.O., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2014, 1:3.
18. Rebiotix completes enrollment for trial using microbiota restoration therapy for treatment of recurrent Clostridium difficile infection, News on February 6, 2014 by Found8tion, (accessed March 2014). http://thefecaltransplantfoundation.org/.
19. Quin J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
20. Arumugam, et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
21. Megerlin F., Lopert T., Taymor K., Trouvin J.H. Biosimilars and the European experience: implications for the United States. Health Aff 2013, 10(32):1803-1810.
22. Megerlin F., Fouassier E. Faecal microbiota transplantation in France: what applicable law?. Ann Pharm Fr 2014, [in press]. 10.1016/j.pharma.2014.04.003.